Table 1.
Baseline characteristics in the NILG compared to the IMS-III trial treatment and control groups and the MR CLEAN, ESCAPE, SWIFT Prime, and REVASCAT trials control groups
| Baseline variable | NILG a reference (n= 136) | IMS-III IV rt-PA+IA a (n = 434) | IMS-III control (n = 222) | p a | MR CLEAN control (n = 267) | P | ESCAPE control (n = 150) | P | SWIFT Prime control (n = 98) | P | REVASCAT control (n = 103) | P | P |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, years | |||||||||||||
| Mean ± SD | 67.3±16 | 66.3±12 | 65.5±13 | 0.50 | n.a. | n.a. | n.a. | n.a. | 66.3±11.3 | 0.60 | 67.2±9.5 | 0.95 | 0.60 |
| Median | 70 | 69 | 68 | 65.7 | 70.0 | n.a. | |||||||
| Range | 28–100 | 23–89 | 23–84 | ||||||||||
|
| |||||||||||||
| Male gender Baseline NIHSS score b | 47.8% (65) | 50.2% (218) | 55.0% (122) | 0.62 | 58.8% (157) | 0.04 | 47.3% (71) | 0.94 | 46.9% (45) | 0.78 | 52.4% (54) | 0.48 | 0.78 |
| Mean ± SD | 18.5±7 | 17.3±5 | 17.0±5 | 0.06 | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Median | 19 | 17 | 16 | 18 | 17 | 17 | 17 | ||||||
| Range | 1–40 | 7–40 | 8–30 | 4–38 | n.a. | n.a. | |||||||
|
| |||||||||||||
| Atrial fibrillation | 39.7% (54) | 35.3% (153) | 31.5% (70) | 0.35 | 25.8% (69) | 0.004 | 40.0% (60) | 0.96 | 39.2% (38/97) | 0.93 | 35.9% (37) | 0.55 | 0.93 |
| Hypertension | 72.8% (99) | 73.5% (319) | 77.0% (171) | 0.87 | n.a. | n.a. | 72.0% (108) | 0.88 | 57.7% (56/97) | 0.02 | 69.9% (72) | 0.62 | 0.02 |
| Diabetes mellitus | 22.8% (31) | 21.7% (94) | 24.3% (54) | 0.78 | 12.7% (34) | 0.01 | 26.0% (39) | 0.53 | 15.5% (15/97) | 0.17 | 18.4% (19) | 0.41 | 0.17 |
| Coronary artery disease | 28.7% (39) | 23.5% (102) | 32.4% (72) | 0.22 | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Mean systolic blood | |||||||||||||
| pressure ± SD, mm Hg | 142.9±27 | 148±21 | 147.3±24 | 0.04 | 145±24.4 | 0.45 | 146 (median) | n.a. | n.a. | n.a. | 144 (median) | n.a. | n.a. |
| Mean TOG ± SD, min | 274±112 | 208±47 | n.a. | <0.00001 | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
|
| |||||||||||||
| Occlusion | (266) | (147) | (94) | (101) | |||||||||
| None | 0% (0) | 19.3% (84) | n.a. | 0.005 | 0% (0) | 1.00 | 0% (0) | 1.00 | 0% (0) | 1.00 | 0% (0) | 1.00 | 1.00 |
| ICA | 26.5% (36) | 15.0% (65) | 0.002 | 29.3% (78) | 0.55 | 26.5% (39) | 0.99 | 16.0% (15) | 0.06 | 27.7% (28) | 0.83 | 0.06 | |
| MCA-M1 | 55.2% (75) | 31.1% (135) | <0.00001 | 62.0% (165) | 0.18 | 71.4% (105) | 0.005 | 76.6% (72) | 0.001 | 64.4% (65) | 0.15 | 0.001 | |
| MCA-M2/M3 c | 8.8% (12) | 23.7% (103) | 0.0003 | 7.9% (21) | 0.75 | 2.0% (3) | 0.02 | 6.4% (6) | 0.50 | 7.9% (8) | 0.80 | 0.50 | |
| Basilar | 9.6% (13) | 1.1% (5) | <0.0001 | 0% (0) | 0.005 | 0% (0) | 0.02 | 0% (0) | 0.04 | 0% (0) | 0.03 | 0.04 | |
Values in parentheses are numbers except where otherwise indicated. Values in italics indicate statistical significance, n.a. = Not available.
a
Comparison between NASA IV rt-PA+Solitaire and IMS-III IV rt-PA+IA.
b
The NIHSS score was obtained prior to endovascular treatment in NASA and prior to IV rt-PA in IMS-III.
c
Multiple M2 occlusion patients were included.